首页> 外文期刊>British Journal of Cancer >Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
【24h】

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband

机译:CHEK2突变携带者一级亲属的癌症风险:先证者的突变类型和癌症部位的影响

获取原文
           

摘要

It is important to have accurate knowledge of the range of cancers associated with various CHEK2 mutations, and of the lifetime risks of cancer associated with each. We wished to establish the relationship between family history, mutation type and cancer risk in families with a CHEK2 mutation. We obtained a blood sample and pedigree information from 2012 unselected women with breast cancer, from 2007 men with prostate cancer and from 1934 patients with colon cancer, from hospitals throughout Poland. Genetic testing was carried out for four founder CHEK2 mutations on all 5953 specimens and 533 carriers were identified. We estimated the risk to age 75 for any cancer in the 2544 first-degree relatives to be 22.3%. After adjusting for mutation type, the risk of breast cancer was much higher among relatives of probands with breast cancer than among relatives of patients with prostate or colon cancer (HR=3.6; 95% CI=2.1–6.2; P=0.0001). Similarly, the risk of prostate cancer was higher among relatives of probands with prostate cancer than among relatives of patients with breast or colon cancer (HR=4.4; 95% CI=2.2–8.7; P=0.0001) and the risk of colon cancer was higher among relatives of probands with colon cancer than among relatives of patients with prostate or breast cancer (HR=4.2; 95% CI=2.4–7.8; P=0.0001). These analyses suggest that the risk of cancer in a carrier of a CHEK2 mutation is dependent on the family history of cancer.
机译:准确了解与各种CHEK2突变相关的癌症范围以及与每种突变相关的癌症的终生风险非常重要。我们希望建立CHEK2突变家族的家族史,突变类型与癌症风险之间的关系。我们从波兰各地医院的2012名未选择的乳腺癌女性,2007年的前列腺癌男性和1934年的结肠癌患者那里获取了血液样本和血统书信息。对所有5953个标本进行了四个创始人CHEK2突变的遗传测试,并鉴定了533个携带者。我们估计2544名一级亲属中任何癌症的75岁风险为22.3%。在调整了突变类型之后,患乳腺癌的先证者的亲属比患前列腺癌或结肠癌的亲属的乳腺癌风险要高得多(HR = 3.6; 95%CI = 2.1-6.2; P = 0.0001)。同样,前列腺癌先证者的亲属患前列腺癌的风险也比乳腺癌或结肠癌患者的亲属要高(HR = 4.4; 95%CI = 2.2-8.7; P = 0.0001),并且患结肠癌的风险也较高。结肠癌先证者的亲属比前列腺癌或乳腺癌患者的亲戚要高(HR = 4.2; 95%CI = 2.4-7.8; P = 0.0001)。这些分析表明,CHEK2突变携带者患癌症的风险取决于癌症的家族史。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号